Agricultural Biotechnology Market Research 2021-2025 | 9.87% Year-Over-Year Growth Rate for 2021 | Technavio

Agricultural Biotechnology Market Research 2021-2025 | 9.87% Year-Over-Year Growth Rate for 2021 | Technavio




Agricultural Biotechnology Market Research 2021-2025 | 9.87% Year-Over-Year Growth Rate for 2021 | Technavio

LONDON–(BUSINESS WIRE)–#GlobalAgriculturalBiotechnologyMarket–Technvaio forecast the global agricultural biotechnology market is expected to grow by USD 25.30 billion during 2021-2025. This marks a significant market slow down compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. However, healthy growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of over 10%.


For the Right Perspective & Competitive Insights- Request Free Sample Report on Pandemic Recovery Analysis

Read the 120-page report with TOC on “Agricultural Biotechnology Market Analysis Report by Application (Transgenic seeds and Crop protection biochemicals), Geography (North America, Europe, APAC, South America, and MEA), and Technology (Genome editing, DNA sequencing, RNAi, and biochips and synthetic biology), and the Segment Forecasts, 2021-2025”. Gain competitive intelligence about market leaders. Track key industry opportunities, trends, and threats. Information on marketing, brand, strategy and market development, sales and supply functions. https://www.technavio.com/report/report/agricultural-biotechnology-market-industry-analysis

The agricultural biotechnology market is driven by the increasing demand for higher crop yields. In addition, the introduction of strong regulatory standards is anticipated to boost the growth of the agricultural biotechnology market.

According to the World Bank, the global population is expected to be 8.24 billion by 2022. The increasing population will result in rising demand for food which can be supplied from land and water resources. Due to increased urbanization, the agricultural land area has reduced, which represents an opposite trend. The adoption of non-conventional farming methods combined with agricultural biotechnology will result in higher yields in both food crops and cash crops. The crop yields can be increased by the biotechnological inputs of GM seeds and crop protection biochemicals. These factors will drive the growth of the global agricultural biotechnology market during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Agricultural Biotechnology Companies:

BASF SE

BASF SE operates its business through Agricultural Solutions, and Other. The company offers agricultural biotechnology services through its segment, BASF Plant Science. Under this segment, the company is focused on developing yield and quality traits, fungal resistant soybeans, and herbicide tolerance in crops such as corn and soybeans.

Bayer AG

Bayer AG operates its business through Pharmaceuticals, Crop science, and Consumer health. The company uses biotechnology to transfer beneficial genes directly into a plant, which allowed for greater efficiency and new opportunities for improving crops.

DuPont de Nemours Inc.

DuPont de Nemours Inc. operates its business through Electronics & Imaging, Nutrition & Biosciences, Transportation & Industrial, Safety & Construction, and Non-Core. The company uses biotechnology to develop new crop varieties with advanced properties.

Eurofins Scientific SE

Eurofins Scientific SE operates its business through Western Europe, North America, and the Rest of the World. The company offers biotechnology services to provide seed trait and crop agronomic assessment resources covering a wide geographic area.

Evogene Ltd.

Evogene Ltd. operates its business through Agriculture, Human Health, and Industrial applications. The company uses biotechnology to develop new crop varieties with advanced properties.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Agricultural Biotechnology Market Application Outlook (Revenue, USD bn, 2020-2025)

  • Transgenic seeds – size and forecast 2020-2025
  • Crop protection biochemicals – size and forecast 2020-2025

Agricultural Biotechnology Market Geography Outlook (Revenue, USD bn, 2020-2025)

  • North America – size and forecast 2020-2025
  • Europe – size and forecast 2020-2025
  • APAC – size and forecast 2020-2025
  • South America – size and forecast 2020-2025
  • MEA – size and forecast 2020-2025

Agricultural Biotechnology Market Technology Outlook (Revenue, USD bn, 2020-2025)

  • Genome editing – size and forecast 2020-2025
  • DNA sequencing – size and forecast 2020-2025
  • RNAi – size, and forecast 2020-2025
  • Biochips and synthetic biology – size and forecast 2020-2025

Are you a start-up willing to make it big in the business? Grab an exclusive Report

Related Reports on Industrials Include:

Global Agricultural Mowers Market– The agricultural mowers market is segmented by product (disc, sickle bar, drum, and flail), geography (North America, Europe, APAC, South America, and MEA), and key vendors. Click Here to Get an Exclusive Free Sample Report

Global Apiculture Market– The apiculture market is segmented by product (honey, beeswax, and others), application (food and beverage, medical, cosmetics, and others), geography (APAC, Europe, North America, MEA, and South America), and key vendors. Click Here to Get an Exclusive Free Sample Report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com
Website: www.technavio.com/

Zealand Pharma announces directed issue and private placement corresponding to approx. 10% of existing share capital

Zealand Pharma announces directed issue and private placement corresponding to approx. 10% of existing share capital




Zealand Pharma announces directed issue and private placement corresponding to approx. 10% of existing share capital

Company announcement – No. 2 / 2021

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW.

THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS WELL AS FINANCIAL STATEMENTS.

  • A directed share offering to institutional and professional investors through an accelerated bookbuilding process will begin immediately.
  • The net proceeds from the offering are expected to be used to help fund commercialization and pre-launch activities for Zealand’s late stage programs, accelerate development of the clinical pipeline, continue support for Zealand’s peptide platform, and for general corporate purposes.
     
  • In connection with the Offering, Zealand will enter into an equity swap agreement to acquire a limited number of New Shares to be used for covering certain ordinary obligations under Zealand’s equity-based incentive programs. Part of the net proceeds will be used to fund the acquisition of these New Shares.
     
  • Zealand’s Chief Executive Officer Emmanuel Dulac and Chief Financial Officer Matthew Dallas have both expressed that they intend to participate in the Offering by subscribing for a limited number of the New Shares.

Copenhagen, 27 January 2021 – Zealand Pharma A/S (“Zealand“) (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announces the launch of an offering of new shares at market price (the “Offering“). The Offering will be completed through an accelerated bookbuilding process and will consist of approx. 4 million new shares (the “New Shares“), representing approx. 10% of Zealand’s currently registered share capital, in a private placement directed at institutional and professional investors in Denmark and certain other jurisdictions.  

Terms of the Offering

The Offering has not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and will be made pursuant to applicable exemptions from the obligation to publish a Danish prospectus in Denmark as well as exemptions from the U.S. Securities Act and the securities laws of other applicable jurisdictions. The Offering will be made at market price and without pre-emption rights for Zealand’s existing shareholders. The Offering is not underwritten.

The subscription price and the total number of New Shares in the Offering will be determined through an accelerated book building process (the “Book building“) as part of the Offering. The Book building for the Offering will open with immediate effect and can close at any time. The offer price and allocation will be determined after the close of the Book building process at Zealand’s discretion. The result of the Offering, the offer price and the total number of New Shares are expected to be announced as soon as practicable thereafter in a company announcement. If the Offering is oversubscribed, an individual allocation of the New Shares will be made.

The New Shares will, if issued, be issued in the systems of VP Securities A/S and delivered to the investors in the temporary ISIN code DK0061531514. No application for admission to trading and official listing has been, or will be, filed for the New Shares issued under the temporary ISIN code, and the temporary ISIN code will only be registered with VP Securities A/S for subscription of the New Shares. The temporary ISIN code in VP Securities A/S will be merged with the permanent ISIN code for the existing shares, DK0060257814, as soon as possible following registration of the share capital increase with the Danish Business Authority. New Shares are, if issued, expected to be admitted to trading and official listing on Nasdaq Copenhagen A/S, in the ISIN code for the existing shares, DK0060257814, following issuance, expectedly on 2 February 2021.

In connection with the Offering, Zealand has agreed to undertake a lock-up commitment for 90 calendar days following admission of the New Shares to trading and official listing on Nasdaq Copenhagen A/S, subject to certain customary exceptions. In addition, the members of Zealand’s executive management and board of directors have agreed to undertake a lock-up commitment for 90 calendar days following the date hereof, subject to certain customary exceptions and an exemption related to shares related to warrants which can be subscribed for by certain members of the executive management and board of directors.

Goldman Sachs International, Jefferies GmbH and Danske Bank A/S are acting as joint global coordinators and joint bookrunners in the Offering and Bryan, Garnier & Co and Nordea Danmark, Filial af Nordea Bank Abp, Finland are acting as co-managers in the Offering (the joint global coordinators and the co-managers are jointly referred to as the “Managers“). Danske Bank A/S is acting as settlement agent for the Offering.

The net proceeds from the offering are expected to be used to help fund commercialization and pre-launch activities for Zealand’s late stage programs, accelerate development of the clinical pipeline, continue support for Zealand’s peptide platform, and for general corporate purposes.

Zealand’s Chief Executive Officer Emmanuel Dulac and Chief Financial Officer Matthew Dallas have both expressed that they intend to participate in the Offering by subscribing for a limited number of the New Shares.

In connection with the Offering, Zealand will enter into an equity swap agreement to acquire a limited number of New Shares to be used for covering certain ordinary obligations under Zealand’s equity based incentive programs. Part of the net proceeds will be used to fund the acquisition of these New Shares.

Share capital increase

The board of directors of Zealand is, if the Offering is completed, expected to exercise its authorization in article 7.1 of Zealand’s articles of association granted by Zealand’s general meeting at the annual general meeting 2 April 2020, to issue the New Shares and increase Zealand’s share capital accordingly.

Expected timetable for the Offering:

The Book building will commence immediately and can close at any time.
Completion of the Offering, including the admission to trading and official listing of the New Shares, is subject to the Offering not being withdrawn prior to the settlement hereof and Zealand making an announcement to that effect.

28 January 2021 Pricing and allocation – announcement of subscription price
1 February 2021 Registration of the New Shares with the Danish Business Authority
1 February 2021 Settlement and payment against delivery of the New Shares. The New Shares will be delivered in the temporary ISIN code
2 February 2021 Admittance to trading and official listing of the New Shares, in the ISIN code for the existing shares, DK0060257814, on Nasdaq Copenhagen A/S
3 February 2021 Merger of the temporary ISIN code with the permanent ISIN code

For further information, please contact:

Zealand Pharma Investor Relations
+45 50 60 38 00
investors@zealandpharma.com

Emmanuel Dulac, President and Chief Executive Officer
EDulac@zealandpharma.com

Matt Dallas, Senior Vice President and Chief Financial Officer
MDallas@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA).

Important information

This announcement is not a prospectus and investors should not purchase any securities referred to in this announcement on the basis of this announcement. The information contained in this announcement is for information and background purposes only and does not purport to be full or complete. No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this announcement or on its completeness, accuracy or fairness. The information in this announcement is subject to change. No obligation is undertaken to update this announcement or correct any inaccuracies, and the distribution of this announcement shall not be deemed to be any form of commitment on the part of Zealand to proceed with any transaction or arrangement referred to herein. This announcement has not been approved by any competent regulatory authority.

This announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, or act as an inducement to enter into, any contract or commitment whatsoever. The transactions described in this announcement and the distribution of this announcement and other information in connection with the transactions in certain jurisdictions may be restricted by law and persons into whose possession this announcement, any document or other information referred to herein comes should inform themselves about, and observe, any such restrictions. In particular, no announcement or information regarding such transactions may be disseminated to the public in any jurisdiction where a prior registration or approval is required for such purpose. Any failure to comply with these or other applicable restrictions may constitute a violation of the securities laws of any such jurisdiction.

In particular, this announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States (including its territories and possessions, any state of the United States and the District of Columbia, the United States), Australia, Canada, Japan or South Africa, or in any other jurisdiction to whom or in which such offer or solicitation is unlawful (“Excluded Territories“). Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The securities referred to in this announcement have not been, and will not be, registered under the U.S. Securities Act or under the securities laws of any state of the United States or any other Excluded Territory. Accordingly, such securities may not be offered, sold, resold or delivered, directly or indirectly, in or into the United States absent registration except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act, and such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into any other Excluded Territories or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities in the United States or elsewhere. Any public offer of such securities to be made in the United States would be made by means of a prospectus that may be obtained from Zealand, which would contain detailed information about the company and management, as well as financial statements. None of Zealand, the Managers or any of their respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents or any other person accepts any responsibility whatsoever if the foregoing restrictions are not complied with by any other person.

This announcement is not for release, publication or distribution in whole or in part in or into the Excluded Territories, except as permitted by applicable law

This announcement has been prepared on the basis that any offers of securities referred to herein will be made pursuant to an exemption from the requirement to publish a prospectus for offers of such securities (i) in any Member State of the EEA under the Prospectus Regulation (EU) 2017/1129 on prospectuses (the “EU Prospectus Regulation“), and (ii) in the United Kingdom, under the Prospectus Regulation (EU) 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”).

The information set forth in this announcement is only being distributed to, and directed at, persons in Member States of the EEA who are qualified investors (“Qualified Investors“) within the meaning of Article 2(1)(e) of the EU Prospectus Regulation.

This announcement is only being distributed to, and is only directed at, persons in the United Kingdom who are qualified investors within the meaning of Article 2(1)(e) of the UK Prospectus Regulation, who are also persons that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order“), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). Any investment or investment activity to which this announcement relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. This announcement must not be acted on or relied on by persons in the United Kingdom who are not relevant persons.

None of Zealand, the Managers or any of their respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents or any other person accepts any responsibility whatsoever for, or makes any representation or warranty, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in this announcement (or whether any information has been omitted from the announcement) or any other information relating to Zealand or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

This announcement does not constitute an investment recommendation. The price and value of securities and any income from them can go down as well as up and you could lose your entire investment. Past performance is not a guide to future performance. Information in this announcement cannot be relied upon as a guide to future performance.

The Managers are acting for Zealand and for no one else in relation to the Offering and will not be responsible to any other person for providing the protections afforded to their clients nor for providing advice in connection with the matters contained in this announcement. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Managers or by any of their affiliates or agents, as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

In connection with the Offering, each of the Managers and any of their respective affiliates or any person acting on its or their behalf, may take up a portion of the shares of the Company in the Offering in a principal position and in that capacity may retain, purchase or sell for its own account such shares and other securities of the Company or related investments and may offer or sell such shares, securities or other investments otherwise than in connection with the Offering. Accordingly, references in this announcement to New Shares being issued, offered or placed should be read as including any issue, offering or placement of such shares in the Company to the Managers or any of their respective affiliates or any person acting on its or their behalf acting in such capacity. In addition, any Manager or any of their respective affiliates or any person acting on its or their behalf may enter into financing arrangements (including swaps, warrants or contracts for difference) with investors in connection with which such Manager(s) or any of their respective affiliates or any person acting on its or their behalf may from time to time acquire, hold or dispose of such securities of the Company, including the New Shares. Furthermore, in the event that the Managers acquire New Shares in the Offering, they may co-ordinate disposals of such shares in accordance with applicable law and regulation. None of the Managers or any of their respective affiliates or any person acting on its or their behalf intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligation to do so.

Forward-Looking Statements

This announcement may contain forward-looking statements, including “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on the beliefs and assumptions and on information currently available to management of Zealand, including with respect to the closing of the Offering described herein. All statements other than statements of historical fact contained in this announcement are forward-looking statements, including statements regarding the anticipated final terms of the Investment. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Zealand’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Zealand’s Annual Report on Form 20-F for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and subsequent reports that Zealand filed or files with the SEC. Forward-looking statements represent Zealand’s beliefs and assumptions only as of the date of this announcement. Although Zealand believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, Zealand assumes no obligation to publicly update any forwardlooking statements for any reason after the date of this announcement to conform any of the forward-looking statements to actual results or to changes in its expectations.

Nextech Announces Acquisition of MyMedLeads

Nextech Announces Acquisition of MyMedLeads




Nextech Announces Acquisition of MyMedLeads

Nextech announces acquisition of MyMedLeads expanding suite of patient engagement and marketing solutions for specialty practices

TAMPA, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) — Nextech Systems, a leading healthcare technology solutions provider for specialty physician practices, today announced the acquisition of MyMedLeads, a patient engagement and marketing software company based in Austin, TX. Founded in 2010, MyMedLeads delivers innovative lead management, marketing automation and patient communication solutions to help medical providers manage their businesses.

This acquisition accelerates Nextech’s strategy of investing in comprehensive EHR, practice management, patient engagement and other value add solutions, extending its offerings in elective specialties like Ophthalmology, Plastic Surgery and Dermatology.

“We are committed to bringing innovative solutions to our customers to help them improve practice efficiency, drive growth and deliver great patient experiences,” said Nextech’s Chief Revenue Officer Wyn Partington. “MyMedLeads is a great example of one of those innovations, and we are thrilled to offer it in a seamlessly integrated way to the thousands of customers who rely on our EHR and Practice Management software to run their practices every day.”

“We have had a long and successful relationship with Nextech as one of their premier partners,” said MyMedLeads Founder and CEO, Enrique Rangel. “This combination reflects our shared belief in our customers’ needs for integrated patient engagement solutions, and I am excited by the innovation we together will bring to our customers.”

About Nextech
Nextech is the complete healthcare technology solution for specialty providers. Since 1997, Nextech has been focused on delivering innovative solutions and services that drive efficiency, fuel growth, and enhance the patient care experience. Nextech services more than 11,000 physicians and over 60,000 office staff in the clinical specialties of Ophthalmology, Dermatology, Orthopedics and Plastic Surgery.

About MyMedLeads
MyMedLeads is a marketing technology software company headquartered in Austin, TX. Founded in 2010, MyMedLeads provides solutions for medical practices in Plastic Surgery and Dermatology to automate patient acquisition and retention efforts, and improve communications with patients. This includes lead management software, marketing automation tools, online scheduling and communication, live chat, patient reviews, and more.

For more information contact:
Wyn Partington
Chief Revenue Officer, Nextech
(813) 425-9260
marketing@nextech.com 

CareRx Announces Increase in Bought Deal Financing to $13 Million

CareRx Announces Increase in Bought Deal Financing to $13 Million




CareRx Announces Increase in Bought Deal Financing to $13 Million

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, Jan. 27, 2021 (GLOBE NEWSWIRE) — CareRx Corporation (“CareRx” or the “Company”) (TSX: CRRX), Canada’s leading provider of specialty pharmacy services to seniors, is pleased to announce that it has entered into an amended agreement pursuant to which Eight Capital and Cormark Securities Inc., as co-lead underwriters and joint bookrunners, together with a syndicate of underwriters (collectively, the “Underwriters”), have now agreed to purchase on a “bought deal” basis 3,059,000 common shares of the Company (the “Shares”) at a price of $4.25 per Share (the “Issue Price“) for aggregate gross proceeds to CareRx of $13,000,750 (the “Offering”).

The Company has granted the Underwriters an option, exercisable, in whole or in part, at any time not later than 30 days following the closing of the Offering, to purchase up to an additional 15% of the Shares at the Issue Price for market stabilization purposes and to cover over-allotments, if any (the “Over-Allotment Option”). If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering will be approximately $14,950,000.

The Shares will be offered by way of (i) a prospectus supplement (the “Prospectus Supplement”) to CareRx’s short form base shelf prospectus dated September 17, 2020, which Prospectus Supplement will be filed with the securities commissions and other similar regulatory authorities in each of the provinces of Canada; (ii) in the United States by way of private placement pursuant to the exemption from registration provided for under Rule 144A of the United States Securities Act of 1933, as amended; and (iii) in jurisdictions outside of Canada and the United States as are agreed to by the Company and the Underwriters on a private placement or equivalent basis.

Concurrent with the closing of the Offering, the Company expects to complete a non-brokered private placement of 1,176,470 common shares, at the Issue Price, for aggregate gross proceeds of $5,000,000, to Yorkville Asset Management Inc. for and on behalf of certain managed funds and Dr. Jack Shevel, each of whom are existing major shareholders of the Company.

The net proceeds of the Offering and the Concurrent Private Placement are expected to be used to satisfy the $4 million cash component of the purchase price payable at closing in connection with the Company’s proposed acquisition of SmartMeds Pharmacy Inc., and for working capital and general corporate purposes.

Each of the Offering and the Concurrent Private Placement is expected to close on or about February 3, 2021 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About CareRx Corporation:

CareRx is Canada’s leading provider of specialty pharmacy services to seniors. We serve approximately 50,000 residents in over 900 seniors and other communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.

Forward Looking Statements:

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable Canadian securities legislation. These forward-looking statements include, among others, statements regarding the Company’s business strategy, plans and other expectations, beliefs, goals, objectives, information and statements about possible future events, including the intended use of proceeds of the Offering and the Concurrent Private Placement. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate” or similar expressions suggesting future outcomes or events. Such forward looking statements reflect management’s current beliefs and are based on information currently available to management.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Factors that could cause such differences include the Company’s liquidity and capital requirements, government regulation and funding, the highly competitive nature of the Company’s industry, reliance on contracts with key customers and other risk factors described from time to time in the reports and disclosure documents filed by the Company with Canadian securities regulatory agencies and commissions. These and other factors should be considered carefully and readers should not place undue reliance on the Company’s forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and neither the Company nor any other person assumes responsibility for the accuracy and completeness of these forward looking statements. The factors underlying current expectations are dynamic and subject to change.

For more information: visit www.carerx.ca or contact: David Murphy, President & Chief Executive Officer, CareRx Corporation, 416-927-8400; Lawrence Chamberlain, Investor Relations, LodeRock Advisors, 416-519-4196, lawrence.chamberlain@loderockadvisors.com.

Pharmacy Times® Expands Its Strategic Alliance Partnership Program With the Addition of Yale Cancer Center

Pharmacy Times® Expands Its Strategic Alliance Partnership Program With the Addition of Yale Cancer Center




Pharmacy Times® Expands Its Strategic Alliance Partnership Program With the Addition of Yale Cancer Center

CRANBURY, N.J.–(BUSINESS WIRE)–#cancerPharmacy Times®, the leading multimedia resource for pharmacy professionals, is excited to announce Yale Cancer Center is now part of its Strategic Alliance Partnership (SAP) program.

“As a world leader in cancer research and education, Yale Cancer Center is devoted to training the next generation of cancer care leaders,” said Gil Hernandez, vice president of Pharmacy & Healthcare Communications, LLC, publisher of Pharmacy Times®. “We look forward to disseminating clinically rooted information to keep health care providers well versed in treatment landscapes, with the greater goal of improving patient outcomes.”

Yale Cancer Center combines a tradition of innovative cancer treatment and quality care for patients. A National Cancer Institute-designated Comprehensive Cancer Center for more than 45 years, Yale Cancer Center is one of 51 such centers in the nation and the only one in Connecticut.

Yale Cancer Center is a collaboration between nationally and internationally renowned scientists and physicians at Yale School of Medicine and Smilow Cancer Hospital at Yale New Haven. This partnership enables the center to provide the best approaches for prevention, detection, diagnosis and treatment of cancer.

“Pharmacists serve as key members of multidisciplinary cancer care teams,” said Kevin Billingsley, M.D., MBA, FACS, chief medical officer at Yale Cancer Center. “Pharmacy Times® provides a special opportunity for our organization to communicate in a more direct and timely way with our pharmacy colleagues around the country.”

The Pharmacy Times® SAP program is a community of advocacy groups and medical associations and institutions that foster collaboration and an open exchange of information among trusted peers for the benefit of patients and their families. As part of this joint effort, Pharmacy Times® will work with Yale Cancer Center to inform and educate practicing pharmacists in Directions in Oncology Pharmacy® and Directions in Health Systems™ publications.

For more information about the Pharmacy Times® SAP program, click here.

About Pharmacy Times®

Pharmacy Times® is the industry-leading multimedia pharmacy network of community, health system, oncology and specialty pharmacy platforms, providing practical clinical and professional information that pharmacists can use every day in their practices when counseling patients and interacting with other health care providers. Each issue and the website contain articles and features covering industry trends, medication errors, drug interactions, patient education, disease state management, patient counseling, product news, pharmacy law and more. Additionally, Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacy Times® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

About Yale Cancer Center and Smilow Cancer Hospital

Yale Cancer Center is one of 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital at Yale New Haven through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital care centers in Connecticut and Rhode Island. Smilow Cancer Hospital is accredited by the Commission on Cancer, a quality program of the American College of Surgeons. Comprehensive Cancer Centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention and innovative cancer treatment.

Contacts

Pharmacy Times® Media Contact
Alexandra Ventura, 609-716-7777

aventura@mjhlifesciences.com

2020 Insights on the Minimal Residual Disease (MRD) – Pipeline Insights – ResearchAndMarkets.com

2020 Insights on the Minimal Residual Disease (MRD) – Pipeline Insights – ResearchAndMarkets.com




2020 Insights on the Minimal Residual Disease (MRD) – Pipeline Insights – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Minimal residual disease (MRD) – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Minimal residual disease (MRD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Diagnosis

There are different criteria for when to test for MRD, based on factors specific to the patient’s disease. Patients may be tested after the final cycle of combination therapy, after bone marrow transplantation, during treatment, after one year on maintenance therapy, or at regular intervals after treatment is completed. The more sensitive a test is, the more effective it is at finding a small amount of cancer cells among the many healthy cells. The most widely used tests to measure MRD are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS).

Minimal residual disease (MRD) Emerging Drugs Chapters

This segment of the Minimal residual disease (MRD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Minimal residual disease (MRD) Emerging Drugs

FLYSYN: Synimmune

FLYSYN is a monospecific antibody for the treatment of acute myeloid leukemia (AML) patients at a stage of minimum residual disease (MRD). FLYSYN is currently evaluated in a Phase I/II study. FLYSYN contains a genetic optimization of its Fc-part resulting in optimized binding to cells expressing the Fc receptor, particularly Natural Killer (NK) cells, and thus substantially improved antibody dependent cell-mediated cytotoxicity (ADCC).

BPX-501: Bellicum Pharmaceuticals

BPX-501 (Rivogenlecleucel) is an allogeneic product consisting of T cells, modified to express the inducible caspase-9 (iC9) safety switch. The treatment is currently under Phase I study in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.

Minimal residual disease (MRD): Therapeutic Assessment

This segment of the report provides insights about the different Minimal residual disease (MRD) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Minimal residual disease (MRD)

There are approx. 8+ key companies which are developing the therapies for Minimal residual disease (MRD).

Phases

This report covers around 8+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Minimal residual disease (MRD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Minimal residual disease (MRD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Minimal residual disease (MRD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Minimal residual disease (MRD) drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Minimal residual disease (MRD) R&D. The therapies under development are focused on novel approaches to treat/improve Minimal residual disease (MRD).
  • In August 2020, Adaptive Biotechnologies announces that US FDA cleared the clonoSEQ assay to detect and monitor minimal residual disease (MRD) in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL).

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Minimal residual disease (MRD) drugs?
  • How many Minimal residual disease (MRD) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Minimal residual disease (MRD)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Minimal residual disease (MRD) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Minimal residual disease (MRD) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Amgen
  • Bellicum Pharmaceuticals
  • Synimmune
  • Novartis
  • AstraZeneca
  • Janssen
  • Shanghai iCELL Biotechnology

Key Products

  • Blinatumomab
  • BPX-501
  • FLYSYN
  • Nilotinib
  • Durvalumab
  • Daratumumab
  • Haploid allogeneic NK cell therapy
  • CTL019

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hdb7st

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

#news #biotech Key switchgrass genes identified, which could mean better biofuels ahead

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Key switchgrass genes identified, which could mean better biofuels ahead .Biologists believe they are one step closer to a long-held goal of making a cheap, widely available plant a source for energy and fuel, meaning one of the next big weapons in the battle against climate change may be able to trace its roots to the side of a Texas highway.

from Biotechnology News – Biology News https://ift.tt/2YlXI2I

Ergotron Partners with UV Angel to Reduce Spread of Pathogens within Healthcare Systems

Ergotron Partners with UV Angel to Reduce Spread of Pathogens within Healthcare Systems




Ergotron Partners with UV Angel to Reduce Spread of Pathogens within Healthcare Systems

Ultraviolet (UV-C) light-equipped workstations eliminate 99% of surface contamination without disrupting caregiver workflow

ST. PAUL, Minn.–(BUSINESS WIRE)–As healthcare providers continue to focus on reducing the spread of pathogens within care facilities, Ergotron and UV Angel® have partnered to offer an ultraviolet (UV-C) light technology solution that safely automates pathogen reduction on workstation surfaces. These accessories are attached above the worksurface or keyboard of Ergotron’s StyleView® medical carts. The solution supports infection prevention measures without disrupting workflows, allowing healthcare workers to stay healthy and focused on providing quality care to their patients.


Amid the COVID-19 pandemic, ensuring the health and safety of healthcare providers and patients has never been more important. Research has shown that the presence of healthcare-associated infection pathogens can be found on 1 in 4 frequently touched surfaces. This demonstrates the critical importance of maintaining clean workspaces to reduce the harmful spread of bacteria, fungi and viruses between patients and caregivers. With the addition of automated UV Angel Adapt™ technology to Ergotron’s StyleView medical carts, up to 99% of surface contamination can be eliminated hundreds of times a day, providing continuous monitoring and pathogen reduction without disruption.

“The partnership with UV Angel underscores Ergotron’s commitment to helping our healthcare customers thrive,” said Mark Brandenhoff, general manager, healthcare at Ergotron. “By adding clinically proven UV-C light technology to our workstations, we’re providing an extra layer of protection, empowering caregivers and other healthcare workers to feel confident they are doing everything they can to stay healthy and safe during this challenging time.”

Studies have shown that people are a primary source of contamination and disease transmission. The recent pandemic has once again highlighted the need to add enhanced source-level controls at the point of contamination. The UV Angel Adapt™ technology has been specifically designed as an engineered source-level control system, operating automatically and independent of other cleaning procedures and infection control measures.

A Stanford University study using UV Angel technology found that UV decontamination significantly slowed the spread of virus DNA, reducing it 90% after 48 hours. As the number of decontaminated surfaces in the hospital increased, the number of viable transmission routes between patients subsequently decreased.

“We believe UV Angel technology is incredibly important to support healthcare workers on the frontlines in the fight against pathogens—especially right now,” said Dr. Linda Lee, chief medical affairs and science officer at UV Angel. “Ergotron is a natural partner for us given their reputation in the industry and large number of StyleView medical carts in use in hospitals, clinics and health systems. Together, we have a tremendous opportunity to make a real difference for caregivers, patients and their families.”

Purchase of the UV Angel Adapt™ technology includes a one-year subscription to a robust, cloud-based analytics software platform for IT professionals to track key performance indicators, access manual and automated cleaning data, and make informed decisions to support infection prevention efforts across the entire fleet.

The UV Angel Adapt™ accessories for StyleView carts will be available in North America in early February. Customers may select to have the light outfitted on the workstation’s keyboard or worksurface. For more information, visit ergotron.com or call 888-743-1119.

About Ergotron

Ergotron, Inc. is a global company focused on improving how people work, learn, play and care for others. Using human-centered design principles and the technology of movement, Ergotron builds solutions that help people thrive in healthcare, education, contract furniture and general office environments. Its custom solutions group develops innovative products for leading global companies in a variety of industries.

Over nearly four decades, the company has earned more than 200 patents and established a growing portfolio of award-winning brands including WorkFit®, CareFit™, LearnFit® and JŪV™. Ergotron is headquartered in St. Paul, Minnesota, with a global sales and marketing presence in North America, Europe and Asia Pacific. All products are designed in the United States and produced in Ergotron’s facilities in St. Paul and China.

About UV Angel

UV Angel is a leading pathogen control technology company creating truly innovative life-changing technologies to make the world a safer place. UV Angel applies years of advanced research and development in engineering, IOT, and ultraviolet light (UV-C) to help make the environments around us cleaner and safer by neutralizing harmful pathogens. Fully automated, patented, and proven safe, the company’s UV-C technology monitors and treats the surfaces we touch and the air we breathe. UV Angel’s technology is complemented by a proprietary data analytics platform that delivers critical insights and strategic advantages to leaders in healthcare, food service, corporate, education and many more industries. Learn more at uvangel.com.

Contacts

Ergotron Contact:
Nikki Hill

651-365-6765

Pr@ergotron.com

UV Angel Contact:
Olivia Lake

269-685-7273

olake@lambert.com

Vizient Forecasts 2.67% Increase in Drug Spend in New Pharmacy Market Outlook; Impact of COVID-19 Continues to be Felt Across Healthcare Ecosystem

Vizient Forecasts 2.67% Increase in Drug Spend in New Pharmacy Market Outlook; Impact of COVID-19 Continues to be Felt Across Healthcare Ecosystem




Vizient Forecasts 2.67% Increase in Drug Spend in New Pharmacy Market Outlook; Impact of COVID-19 Continues to be Felt Across Healthcare Ecosystem

IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. today released its Winter 2021 Pharmacy Market Outlook, projecting a 2.67% increase in the price of pharmaceuticals purchased by health systems, academic medical centers, pediatric hospitals, and non-acute practices, for the period July 1 – June 30, 2022. Formerly named the Drug Price Forecast, the Outlook’s projected increase continues to trend slightly downward, reflecting recent generic entrants to the market as well as increasing adoption of biosimilars. Findings also include a similar overall increase for oncology spend, which makes up nearly a quarter of Vizient member pharmaceutical spend, a potential increase in cancer mortality due to the impact of COVID-19 on screenings as well as COVID’s inflationary impact on plasma-derived products. The full report can be accessed here.

“The trend toward more moderate drug price increases is a welcome one, given the financial difficulties created by the pandemic,” said Dan Kistner, group senior vice president, pharmacy solutions for Vizient. “Even so, without question the pandemic continues to have an impact on clinical and financial outcomes. Increased use of high-cost drugs vasopressin and tocilizumab as well as many critical care drugs used to treat COVID patients are continuing to impact budgets.”

A new formulation of vasopressin was recently approved by the FDA and granted market exclusivity through 2035, causing its price to spike significantly. Fortunately, several substantial price decreases are projected for drugs like injectable acetaminophen, daptomycin, a commonly used antibiotic, and regadenoson, a medication used in cardiac stress testing, further illustrating the importance of generic and biosimilar competition. The drug with the largest anticipated price increase remains adalimumab, sold under the brand name Humira® and used to treat arthritis and ulcerative colitis. As biosimilar competition is not yet allowed to be marketed, adalimumab, which is already the No. 1 drug by total spend for Vizient members and the U.S. health system alike, is projected to increase in price by 7.5% over the next 18 months.

Other highlights from the Outlook include:

Impact of COVID-19 on cancer treatment. Oncology medications, which make up 24.67% of pharmaceutical purchases, are projected to increase 2.68%. Wholesale acquisition cost for intravenous drug pegaspargase increased 19.2% in 2020. The oral medication nilotinib increased 15.5%.

More concerning, data from the Vizient Clinical Data Base for non-inpatient cancer show that screening rates for breast, colon, and cervical cancer plummeted in April, which contributed to a 65.2% decline in the incidence of new cancer diagnoses as of May. Delays in detection and diagnosis of cancer can have a significant impact on patient outcomes. While screenings recovered by August, research from the Cancer Network, home of the journal Oncology, suggests mortality increases up to 9.5% from breast cancer and up to 16.6% for colorectal cancer within five years. The long-term impact of COVID-19 on cancer patients remains a critical metric to track.

Plasma critical care products: IgIV and albumin Even prior to the pandemic, prices for albumin and other plasma-derived products have remained a closely monitored issue. Vizient projects supply to tighten in the first quarter of 2021 due to a reduction in plasma donations because of stay-at-home orders and public concerns about contracting the virus and potentially remain tight into 2022 resulting in a 3.10% inflation rate for these products.

Biosimilars: almost there? After ten years on the market, biosimilars are poised to make their greatest impact yet in the next half decade. As of Dec. 31, the FDA had approved 29 biosimilars with many yet to be launched due to patent settlements. A recent analysis shows the availability of biosimilars resulted in cost savings of $19 billion between 2015 and 2019. That savings is expected to quintuple by 2024 to $104 billion. Biosimilar versions of trastuzumab, a chemotherapy used to treat breast, stomach and esophageal cancers, grew to a 39% share in September, but the further increase in savings will come largely when biosimilars for adalimumab come to market in 2023.

Given the interest in cost savings, and as the health care industry begins to recover from the pandemic, those savings should inspire a continued industry shift toward biosimilars. “It’s not yet possible to determine the total expense associated with COVID-19 on the health care industry. We know that spend on COVID-related drugs began to decline in the second quarter of last year, but we saw an uptick of $60.5 million over five of the most commonly used COVID-related drugs in the third quarter of 2020 compared to the same quarter in 2019,” said Kistner.

The Vizient Pharmacy Market Outlook is available for download on this resource center, info.vizientinc.com/pharmacy-market-outlook, along with additional cost reduction information. Vizient is an important resource for pharmacy leaders in developing annual budget projections for their health systems. Vizient conducts the pricing analysis biannually to provide insight on factors driving pricing and practice changes in the pharmaceutical industry.

About Vizient, Inc.

Vizient, Inc. provides solutions and services that improve the delivery of high-value care by aligning cost, quality and market performance for more than 50% of the nation’s acute care providers, which includes 95% of the nation’s academic medical centers, and more than 20% of ambulatory care providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $100 billion in annual purchasing volume, to improve patient outcomes and lower costs. Vizient has earned a World’s Most Ethical Company designation from the Ethisphere Institute every year since its inception. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

Contacts

Donna Ledbetter

(972) 830-6321

donna.ledbetter@vizientinc.com

ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury

ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury




ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury

EINDHOVEN, Netherlands & LAUSANNE, Switzerland–(BUSINESS WIRE)–ONWARD today announced the publication of a study in the journal, Nature, which found targeted electrical spinal cord stimulation stabilizes blood pressure in people with spinal cord injury (SCI).

A serious and underrecognized result of spinal cord injury is unstable blood pressure, which can have devastating consequences that reduce quality of life and are life threatening. Unfortunately, there are no effective therapies for unstable blood pressure after spinal cord injury,” said Dr. Aaron Phillips, PhD, a member of the Hotchkiss Brain Institute and Libin Cardiovascular Institute at the Cumming School of Medicine (CSM) and co-lead author of the study. “We created the first platform to understand the mechanisms underlying blood pressure instability after spinal cord injury, which allowed us to develop a new cutting-edge solution.”

Loss of movement and sensation are the most commonly known impacts of spinal cord injury, but SCI is also frequently accompanied by other effects that challenge activities of daily living. Blood pressure instability is one such effect, making it difficult for people with SCI to change body position – moving from lying to sitting to standing. In this study, researchers from University of Calgary, Swiss Federal Institute of Technology (EPFL), and University Hospital Lausanne (CHUV) demonstrated they could quickly and accurately normalize blood pressure with electrical spinal cord stimulation. Stabilization was observed in rodents and non-human primates for extended periods after acute and chronic spinal cord injury, and the approach also showed promise in humans.

This research is a breakthrough in the fundamental understanding of how blood pressure regulatory circuits function in people with SCI and sets the foundation for further studies assessing the use of electrical spinal cord stimulation to regulate blood pressure and other autonomic functions in people with SCI.

We used similar concepts and technologies to restore walking after paralysis and are now pleased to leverage those advances to address this very common but serious effect of SCI,” said Dr. Grégoire Courtine, PhD, Professor at EPFL, Director of .NeuroRestore, and co-lead author of the study. “We look forward to working with ONWARD to conduct clinical trials in humans so this approach can be translated into a viable therapeutic option for people with SCI.”

This research will be further advanced by a $36 million contract granted by the United States Defense Advanced Research Project Agency (DARPA) for a five-year project to develop neurotherapeutics that bridge the gap between the spinal cord and the brain after spinal cord injury. The DARPA contract enables an alliance of 12 institutions around the world that includes EPFL, University of Calgary and ONWARD to conduct groundbreaking research in the pursuit of new therapies for spinal cord injury. DARPA has helped develop major technological advancements including the internet, GPS and Speech Interpretation and Recognition Interface (SIRI.)

About ONWARD

ONWARD (@onwdempowered), formerly known as GTX Medical, is a medical technology company focused on the development and commercialization of innovative therapies to facilitate functional recovery of people with spinal cord injury. Driven by a mission to restore movement, independence, and health in people with spinal cord injury, ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. Both of ONWARD’s technology platforms have been awarded Breakthrough Device Designation by the FDA.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands and the EPFL Innovation Park in Lausanne, Switzerland, with a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com and follow us on Twitter and LinkedIn.

Contacts

For general inquiries, please contact:

info@onwd.com

For media inquiries, please contact:

Laura Vinci, Finn Partners

laura.vinci@finnpartners.com
+14024998203